to inflammation. Stable disease Disease that was asymptomatic or causing symptoms but at an acceptable level as reported by the patient. A minimum of 6 months was required to qualify as clinically stable. Primary nonresponse Absence of a clinically meaningful improvement in disease activity over the 3 to 6 months after treatment initiation, not related to toxicity or poor adherence. Secondary nonresponse Recurrence of ankylosing spondylitis activity, not due to treatment interruption or poor